These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31929430)

  • 21. Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.
    Sato T; Ichinohe T; Kanda J; Yamashita K; Kondo T; Ishikawa T; Uchiyama T; Takaori-Kondo A
    Int J Hematol; 2011 Apr; 93(4):532-541. PubMed ID: 21465116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset.
    Bohmann EM; Fehn U; Holler B; Weber D; Holler E; Herr W; Hoffmann P; Edinger M; Wolff D
    Ann Hematol; 2017 Feb; 96(2):299-310. PubMed ID: 27942862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT.
    Czerw T; Labopin M; Giebel S; Socié G; Volin L; Fegueux N; Masszi T; Blaise D; Chaganti S; Cornelissen JJ; Passweg J; Maertens J; Itälä-Remes M; Wu D; Mohty M; Nagler A
    Cancer; 2018 Jun; 124(12):2523-2533. PubMed ID: 29603136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.
    Lee SJ; Klein JP; Barrett AJ; Ringden O; Antin JH; Cahn JY; Carabasi MH; Gale RP; Giralt S; Hale GA; Ilhan O; McCarthy PL; Socie G; Verdonck LF; Weisdorf DJ; Horowitz MM
    Blood; 2002 Jul; 100(2):406-14. PubMed ID: 12091329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation.
    Hao B; Gao S; Sang YW; Wang L; Meng XQ; You JY
    J Zhejiang Univ Sci B; 2019 Oct.; 20(10):849-860. PubMed ID: 31489804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD.
    Moon JH; Hamad N; Sohn SK; Uhm J; Alam N; Gupta V; Lipton JH; Messner HA; Seftel M; Kuruvilla J; Kim DD
    Ann Hematol; 2017 May; 96(5):805-815. PubMed ID: 28214979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus.
    Lutz M; Kapp M; Einsele H; Grigoleit GU; Mielke S
    Clin Transplant; 2014 Dec; 28(12):1410-5. PubMed ID: 25287756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-Time PCR Analysis of Chimerism in T Cell Subsets as an Early Predictor of Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplantation.
    Guz K; Nasiłowska B; Tomaszewska A; Orzińska A; Smolarczyk-Wodzyńska J; Krzemienowska M; Hałaburda K; Przybylski M; Jędrzejczak WW; Mariańska B; Brojer E
    Ann Transplant; 2015 Dec; 20():720-8. PubMed ID: 26632547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of autoantibody expression in allogeneic stem-cell recipients.
    Moon JH; Lee SJ; Kim JG; Chae YS; Kim SN; Kang BW; Suh JS; Lee KS; Sohn SK
    Transplantation; 2009 Jul; 88(2):242-50. PubMed ID: 19623021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of Genetic Variation as a Predictive Biomarker for Chronic Graft-Versus-Host-Disease After Allogeneic Stem Cell Transplantation.
    Partanen J; Hyvärinen K; Bickeböller H; Bogunia-Kubik K; Crossland RE; Ivanova M; Perutelli F; Dressel R
    Front Immunol; 2020; 11():575492. PubMed ID: 33193367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease.
    Balon J; Hałaburda K; Bieniaszewska M; Reichert M; Bieniaszewski L; Piekarska A; Pawłowski R; Hellmann A
    Bone Marrow Transplant; 2005 Jun; 35(11):1083-8. PubMed ID: 15821766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydrogen in Patients With Corticosteroid-Refractory/Dependent Chronic Graft-Versus-Host-Disease: A Single-Arm, Multicenter, Open-Label, Phase 2 Trial.
    Qian L; Liu M; Shen J; Cen J; Zhao D
    Front Immunol; 2020; 11():598359. PubMed ID: 33324415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy.
    Pérez-Simón JA; Encinas C; Silva F; Arcos MJ; Díez-Campelo M; Sánchez-Guijo FM; Colado E; Martín J; Vazquez L; Del Cañizo C; Caballero D; San Miguel J
    Biol Blood Marrow Transplant; 2008 Oct; 14(10):1163-1171. PubMed ID: 18804047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome.
    Zecca M; Prete A; Rondelli R; Lanino E; Balduzzi A; Messina C; Fagioli F; Porta F; Favre C; Pession A; Locatelli F;
    Blood; 2002 Aug; 100(4):1192-200. PubMed ID: 12149197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The clinical characteristics of polyserositis as main presentation of chronic graft-versus-host rejection disease after allogeneic hematopoietic stem cell transplantation].
    Wang Q; Li Y; Qiu Z; Xu W; Sun Y; Wang L; Wang M; Liu W; Dong Y; Ou J; Wang W; Liang Z; Wang Q; Cen X; Ren H
    Zhonghua Nei Ke Za Zhi; 2014 May; 53(5):394-7. PubMed ID: 25146408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.
    Arora M; Wagner JE; Davies SM; Blazar BR; Defor T; Enright H; Miller WJ; Weisdorf DF
    Biol Blood Marrow Transplant; 2001; 7(5):265-73. PubMed ID: 11400948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene expression profiling-based identification of CD28 and PI3K as new biomarkers for chronic graft-versus-host disease.
    Lai P; Weng J; Lu Z; Guo R; Luo C; Wu S; Ling W; Geng S; Du X
    DNA Cell Biol; 2011 Dec; 30(12):1019-25. PubMed ID: 21682596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pentraxin-3 levels in graft-versus-host disease during allogeneic hematopoietic stem cell transplantation.
    Doehn JM; Winkler A; Kuzmina Z; Hladik A; Greinix H; Knapp S; Robak O
    Exp Hematol; 2016 Oct; 44(10):917-23. PubMed ID: 27403536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis.
    Fante MA; Holler B; Weber D; Angstwurm K; Bergler T; Holler E; Edinger M; Herr W; Wertheimer T; Wolff D
    Ann Hematol; 2020 Sep; 99(9):2181-2190. PubMed ID: 32715339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The benefit of chronic graft-versus-host disease in patients with acute myeloid leukemia relapsed after allogeneic stem cell transplantation.
    Wang Z; Yin C; Zhang W; Tang W; Song X; Hu X; Ni X; Qiu H; Yang J; Hu J; Wang J
    Ann Hematol; 2019 Jul; 98(7):1765-1773. PubMed ID: 30993416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.